{
    "0PQ.F": {
        "short_name": "PROQR THERAPEUTICS EO-,04",
        "long_name": "ProQR Therapeutics N.V.",
        "summary": "ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Leiden"
    },
    "2GH.F": {
        "short_name": "MERUS N.V.  EO -,09",
        "long_name": "Merus N.V.",
        "summary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations with Caris Life Sciences to detect NRG1 fusions in cancer patients; and Loxo Oncology at Lilly to discover novel T-Cell Re-directing bispecific antibodies. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Utrecht"
    },
    "5C1A.F": {
        "short_name": "ESPERITE N.V.",
        "long_name": "Esperite N.V.",
        "summary": "Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally. It operates through four segments: Stem Cell, The Cell Factory, Genoma, and Other. The company collects, processes, and stores human adult stem cells from the umbilical cord blood and the umbilical cord. It also provides proteomics and genomics predictive medicines; and implements its proprietary technology for clinical grade production of autologous mesenchymal and stromal stem cells. In addition, it develops AGAATA, a diagnostic system based on the next generation sequencing technology, as well as allows laboratories to perform their own genetic analysis with the bioinformatics and methods developed by Genoma. The company's products portfolio includes Tranquility, a non-invasive prenatal test; and Cryosave's whole genome sequencing, carrier screening tests, and other products. Further, it engages in biobanking cord blood and cord tissue stem cells business. The company was formerly known as Cryo-Save Group N.V. and changed its name to Esperite N.V. in July 2014. Esperite N.V. was founded in 2000 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "ARGX": {
        "short_name": "argenx SE",
        "long_name": "argenx SE",
        "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.\u00c3\u0080.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Breda"
    },
    "ARGX.BR": {
        "short_name": "ARGENX SE",
        "long_name": "argenx SE",
        "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.\u00c3\u0080.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Netherlands",
        "city": "Breda"
    },
    "ARGX.VI": {
        "short_name": "ARGENX SE",
        "long_name": "argenx SE",
        "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.\u00c3\u0080.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Netherlands",
        "city": "Breda"
    },
    "ESP.AS": {
        "short_name": "ESPERITE",
        "long_name": "Esperite N.V.",
        "summary": "Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally. It operates through four segments: Stem Cell, The Cell Factory, Genoma, and Other. The company collects, processes, and stores human adult stem cells from the umbilical cord blood and the umbilical cord. It also provides proteomics and genomics predictive medicines; and implements its proprietary technology for clinical grade production of autologous mesenchymal and stromal stem cells. In addition, it develops AGAATA, a diagnostic system based on the next generation sequencing technology, as well as allows laboratories to perform their own genetic analysis with the bioinformatics and methods developed by Genoma. The company's products portfolio includes Tranquility, a non-invasive prenatal test; and Cryosave's whole genome sequencing, carrier screening tests, and other products. Further, it engages in biobanking cord blood and cord tissue stem cells business. The company was formerly known as Cryo-Save Group N.V. and changed its name to Esperite N.V. in July 2014. Esperite N.V. was founded in 2000 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "AMS",
        "market": "nl_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "IGPH.SW": {
        "short_name": "IGEA Pharma N",
        "long_name": "IGEA Pharma N.V.",
        "summary": "IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in in the United States. The company offers Alz1, an at-home lab test kit to measure non-bound copper in the blood; and dietary supplement products to reduce blood heavy metals content under the Alz1 Tab brand. It also provides dry aerosol generators for air and inanimate environmental surfaces sanitization, as well as air sterilization and purification devices. The company also engages in laboratory analysis. IGEA Pharma N.V. was incorporated in 2015 and is headquartered in Hoofddorp, the Netherlands.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Netherlands",
        "city": "Hoofddorp"
    },
    "K3P.F": {
        "short_name": "KIADIS PHARMA NV  EO -,10",
        "long_name": "Kiadis Pharma N.V.",
        "summary": "Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. The company develops K-NK002 as an adjunctive immunotherapeutic, which is in Phase II clinical trials for blood cancer patients undergoing a haploidentical HSCT with the post-transplant cyclophosphamide (PTCy) protocol; and K-NK003, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia relapse/refractory (AML R/R). The company's preclinical stage product include K-NK00X, a NK-cell therapy candidate for the treatment of various solid tumors. It has a collaboration agreement with Harbour BioMed, Utrecht University, Erasmus Medical Center, and Viroclinics-DDL for the development of a combination of a monoclonal antibody and natural killer cells as a treatment for COVID-19. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "KDS.AS": {
        "short_name": "KIADIS",
        "long_name": "Kiadis Pharma N.V.",
        "summary": "Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. The company develops K-NK002 as an adjunctive immunotherapeutic, which is in Phase II clinical trials for blood cancer patients undergoing a haploidentical HSCT with the post-transplant cyclophosphamide (PTCy) protocol; and K-NK003, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia relapse/refractory (AML R/R). The company's preclinical stage product include K-NK00X, a NK-cell therapy candidate for the treatment of various solid tumors. It has a collaboration agreement with Harbour BioMed, Utrecht University, Erasmus Medical Center, and Viroclinics-DDL for the development of a combination of a monoclonal antibody and natural killer cells as a treatment for COVID-19. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "AMS",
        "market": "nl_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "MRUS": {
        "short_name": "Merus N.V.",
        "long_name": "Merus N.V.",
        "summary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations with Caris Life Sciences to detect NRG1 fusions in cancer patients; and Loxo Oncology at Lilly to discover novel T-Cell Re-directing bispecific antibodies. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Utrecht"
    },
    "PHAR": {
        "short_name": "Pharming Group N.V.",
        "long_name": "Pharming Group N.V.",
        "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Leiden"
    },
    "PHG": {
        "short_name": "Koninklijke Philips N.V. NY Reg",
        "long_name": "Koninklijke Philips N.V.",
        "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "PHGN.F": {
        "short_name": "PHARMING GRP  EO-,01",
        "long_name": "Pharming Group N.V.",
        "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Leiden"
    },
    "PHGUF": {
        "short_name": "PHARMING GROUP NV",
        "long_name": "Pharming Group N.V.",
        "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Leiden"
    },
    "PHIA.AS": {
        "short_name": "PHILIPS KON",
        "long_name": "Koninklijke Philips N.V.",
        "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "AMS",
        "market": "nl_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "PHIA.F": {
        "short_name": "KONINKL. PHILIPS ADR -,20",
        "long_name": "Koninklijke Philips N.V.",
        "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "PHIA.MI": {
        "short_name": "PHILIPS",
        "long_name": "Koninklijke Philips N.V.",
        "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MIL",
        "market": "it_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "PHIA.VI": {
        "short_name": "PHILIPS NV",
        "long_name": "Koninklijke Philips N.V.",
        "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "PHIAN.MX": {
        "short_name": "KONINKLIJKE PHILIPS NV",
        "long_name": "Koninklijke Philips N.V.",
        "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Laboratories & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "PRQR": {
        "short_name": "ProQR Therapeutics N.V.",
        "long_name": "ProQR Therapeutics N.V.",
        "summary": "ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Leiden"
    },
    "QGEN": {
        "short_name": "Qiagen N.V.",
        "long_name": "QIAGEN N.V.",
        "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Venlo"
    },
    "QGEN.VI": {
        "short_name": "QIAGEN NV",
        "long_name": "QIAGEN N.V.",
        "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Netherlands",
        "city": "Venlo"
    },
    "QIA.DE": {
        "short_name": "QIAGEN NV  EO -,01",
        "long_name": "QIAGEN N.V.",
        "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "Netherlands",
        "city": "Venlo"
    },
    "QIA.F": {
        "short_name": "QIAGEN NV  EO -,01",
        "long_name": "QIAGEN N.V.",
        "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Venlo"
    },
    "QURE": {
        "short_name": "uniQure N.V.",
        "long_name": "uniQure N.V.",
        "summary": "uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "RYLPF": {
        "short_name": "KONINKLIJKE PHILIPS NV",
        "long_name": "Koninklijke Philips N.V.",
        "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "SAE.DE": {
        "short_name": "SHOP APOTHEKE EUROPE INH.",
        "long_name": "Shop Apotheke Europe N.V.",
        "summary": "Shop Apotheke Europe N.V. owns and operates online pharmacies in Germany, Belgium, Austria, Switzerland, the Netherlands, France, Italy, and Spain. It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal care products. The company was founded in 2001 and is headquartered in Sevenum, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "GER",
        "market": "de_market",
        "country": "Netherlands",
        "city": "Sevenum"
    },
    "SAE.F": {
        "short_name": "SHOP APOTHEKE EUROPE INH.",
        "long_name": "Shop Apotheke Europe N.V.",
        "summary": "Shop Apotheke Europe N.V. owns and operates online pharmacies in Germany, Belgium, Austria, Switzerland, the Netherlands, France, Italy, and Spain. It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal care products. The company was founded in 2001 and is headquartered in Sevenum, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Sevenum"
    },
    "SAEYY": {
        "short_name": "SHOP APOTHEKE EUROPE NV UNSPON ",
        "long_name": "Shop Apotheke Europe N.V.",
        "summary": "Shop Apotheke Europe N.V. owns and operates online pharmacies in Germany, Belgium, Austria, Switzerland, the Netherlands, France, Italy, and Spain. It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal care products. The company was founded in 2001 and is headquartered in Sevenum, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Sevenum"
    },
    "SHOP.VI": {
        "short_name": "SHOP APOTHEKE EUROPE NV",
        "long_name": "Shop Apotheke Europe N.V.",
        "summary": "Shop Apotheke Europe N.V. owns and operates online pharmacies in Germany, Belgium, Austria, Switzerland, the Netherlands, France, Italy, and Spain. It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal care products. The company was founded in 2001 and is headquartered in Sevenum, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Netherlands",
        "city": "Sevenum"
    },
    "SHPPF": {
        "short_name": "SHOP APOTHEKE EUROPE NV",
        "long_name": "Shop Apotheke Europe N.V.",
        "summary": "Shop Apotheke Europe N.V. owns and operates online pharmacies in Germany, Belgium, Austria, Switzerland, the Netherlands, France, Italy, and Spain. It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal care products. The company was founded in 2001 and is headquartered in Sevenum, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Sevenum"
    }
}